By Risa Kerslake, RN, BSN
For decades, the clinical focus on sleep disorders like narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) has been almost exclusively fixed on a single, hallmark symptom: excessive daytime sleepiness (EDS). While EDS—the overwhelming urge to fall asleep during the day—is undeniably the defining clinical feature of these conditions, a growing body of evidence suggests that clinicians and researchers have been overlooking a equally debilitating companion symptom: chronic, persistent fatigue.
New findings from the ASPIRE survey, presented at the SLEEP 2026 conference, indicate that fatigue is not merely a byproduct of sleepiness but a distinct, widespread, and deeply burdensome clinical reality. Even among patients actively managing their conditions with current standard-of-care stimulants and wake-promoting agents, the prevalence of fatigue remains alarmingly high, suggesting a significant gap in the current therapeutic landscape.
Main Facts: Redefining the Patient Experience
The ASPIRE study, a large-scale, real-world assessment of 366 adults, was designed to bridge the gap between anecdotal patient reports and empirical clinical data. Led by Michael Doane, PhD, head of health economics and outcomes research at Alkermes, the study aimed to characterize the burden of symptoms that often fall outside the traditional scope of narcolepsy and IH treatment protocols.
The study’s most striking finding is the sheer ubiquity of fatigue. Among the 366 participants, a staggering 91% reported levels of fatigue classified as "mild-to-severe" based on the PROMIS-Fatigue Short-Form 6a instrument. This statistic held firm across all subgroups—NT1, NT2, and IH—challenging the historical assumption that fatigue is secondary to sleepiness or that it is uniquely linked to specific subtypes.
"One of the things that stood out was how prevalent these symptoms are and how consistent that is across the different populations we looked at," says Dr. Doane. The data suggests that for the vast majority of these patients, the daily struggle involves a persistent, heavy exhaustion that survives current pharmaceutical interventions.
Chronology: From Anecdote to Empirical Evidence
The path to this discovery has been marked by a shift in how researchers view patient-reported outcomes (PROs). For years, the scientific literature relied heavily on qualitative, anecdotal evidence. While patient forums and support groups have long discussed the difference between "sleepiness" (the inability to stay awake) and "fatigue" (a pervasive lack of energy and cognitive stamina), this distinction was rarely quantified in large-scale clinical trials.
- Pre-2026: Research focus remains locked on EDS and cataplexy. Patients report dissatisfaction with treatment outcomes despite improvements in sleepiness scores.
- Early 2026: The ASPIRE study design is finalized, focusing on "real-world" participants rather than controlled trial environments. The goal is to capture the patient experience in their daily lives, including those already on prescription medications.
- May 2026: Results of the ASPIRE survey are presented at the SLEEP 2026 conference. The data provides, for the first time, a clear statistical link between fatigue severity and socioeconomic outcomes like work productivity and quality of life.
- Post-2026: The findings serve as a catalyst for new drug development programs, such as the alixorexton trials, which aim to target multiple neurological pathways rather than just the arousal centers of the brain.
Supporting Data: The Economic and Human Cost
The ASPIRE study did not stop at identifying the presence of fatigue; it quantified the impact of that fatigue on the lives of patients. By utilizing the Work Productivity and Activity Impairment Questionnaire (WPAI) and the EQ-5D-5L health-related quality of life scale, the research team created a clear map of how fatigue infiltrates the daily life of a patient with hypersomnia.
When researchers compared patients with "mild-to-severe" fatigue against those reporting "normal" levels, the discrepancies were stark:
- Work Impairment: Those suffering from high levels of fatigue reported a 59% rate of work impairment, compared to just 21% in the "normal" group. This includes absenteeism (missed work) and "presenteeism" (being physically at work but mentally or physically unable to function at full capacity).
- Activity Impairment: The gap widened regarding daily activity, with 66% of the high-fatigue group reporting significant impairment in social and household activities, compared to 28% of those with normal levels.
- Quality of Life: Health-related quality of life scores were significantly lower across the board for the high-fatigue group, indicating that the impact of the condition extends far beyond the professional sphere and into the personal and psychological wellbeing of the patient.
Dr. Doane notes that these findings are likely conservative. "One limitation of survey research is that these studies typically enroll patients who are well-connected, healthy, and interested enough to participate in research," he explains. "Individuals who aren’t healthy or doing well related to their condition are unlikely to participate. If anything, we’re probably underestimating just how prevalent and how bothersome these symptoms are."
Official Responses and Clinical Implications
The implications of the ASPIRE study are profound for both the pharmaceutical industry and the clinical community. For clinicians, the data acts as a "call to action" to move beyond the traditional metrics of EDS.
"Clinicians should consider symptoms beyond excessive daytime sleepiness," Dr. Doane emphasizes. "It’s thinking about more than that hallmark symptom, knowing that patients experience many other symptoms that are also just as bothersome."
This shift in thinking is already influencing the development of next-generation treatments. Alkermes is currently spearheading the alixorexton program, which evaluates an orexin receptor 2 agonist in Phase 3 trials (the Brilliance trials for NT1/NT2 and the Vibrance-3 trial for IH). The objective is to move away from the "stimulant-only" paradigm—which often masks sleepiness but does not address the systemic, underlying fatigue—and toward therapies that provide more comprehensive neurological support.
"As we look toward the future, we’re excited to bring a potential treatment to patients that can address multiple symptoms," says Dr. Doane. He argues that future clinical trials must include these fatigue measures as key outcome benchmarks to ensure that a "successful" drug is one that actually returns a patient to a functional quality of life, rather than one that simply keeps them awake.
The Future of Hypersomnia Care
The ASPIRE survey results highlight a critical disconnect in current care: patients are often labeled as "treated" because their sleepiness has improved, even as they remain functionally disabled by deep, persistent fatigue. This "hidden" population represents a major unmet need in modern medicine.
Moving forward, the challenge for the medical community is twofold:
- Diagnostic Refinement: Implementing standard screening tools, such as the PROMIS-Fatigue scale, in routine clinical visits to ensure that fatigue is being tracked with the same rigor as sleepiness.
- Therapeutic Innovation: Supporting the development of novel agents that address the diverse, multifactorial nature of hypersomnias, acknowledging that these conditions are not just "sleep disorders" but complex neurological syndromes that affect energy metabolism, cognitive clarity, and daily stamina.
As the research community digests the ASPIRE findings, the message is clear: the era of focusing solely on the "sleepy patient" must come to an end. By acknowledging the full spectrum of the patient experience—including the debilitating, pervasive fatigue that remains despite current treatments—the medical field can begin to develop more holistic, effective strategies that restore not just the ability to stay awake, but the ability to live a full and productive life.
Reference
Michael Doane, Jane Lazar Tucker, Kristen McCausland, et al. 0699 Real-world experience and impact of fatigue in narcolepsy and idiopathic hypersomnia: Survey results from the ASPIRE study. Sleep. May 2026 (suppl_1);49:A311-2.
